Royalty Pharma officer proposes $161K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Royalty Pharma plc (RPRX) officer Gregory Norden reported a proposed sale of 3,045 common shares, with an aggregate market value of $161,385.00 and an approximate sale date of May 14, 2026. He acquired the shares on May 13, 2026, through vesting of restricted stock unit awards granted under the issuer’s equity compensation plan. The notice lists February 12, 2026, as the plan adoption or instruction date if relying on Rule 10b5-1.
Key Figures
Key Terms
Rule 10b5-1 regulatory
restricted stock unit awards financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Rule 10b5-1 date is listed in Gregory Norden’s RPRX notice?
AI-generated analysis. How Rhea-AI works. Not financial advice.